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Encephalitis is a rare, but serious complication from vaccination against smallpox using replication competent strains of vaccinia virus. In
this report we describe mutants of vaccinia virus, containing N-terminal deletions of the vaccinia virus interferon resistance gene, E3L, that
are attenuated for neuropathogenesis in a mouse model system. These recombinant viruses replicated to high titers in the nasal mucosa after
intra-nasal infection of C57BL/6 mice but failed to spread to the lungs or brain. These viruses demonstrated reduced pathogenicity after intra-
cranial infection as well, indicating a decrease in neurovirulence. Intra-nasal inoculation or inoculation by scarification with a low dose of
recombinant virus containing a deletion of the entire N-terminal domain of E3L protected against challenge with a high dose of wild-type
vaccinia virus, suggesting that this replication competent, but attenuated strain of vaccinia virus may have promise as an improved vaccine
for protecting against smallpox, and as a vector for inducing mucosal immunity to heterologous pathogenic organisms.
D 2005 Published by Elsevier Inc.
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Vaccinia virus (VV) is a powerful immunogen, with a
single dose often providing long-term protection against
smallpox (Fenner et al., 1988). However, nearly 1 in 1000
vaccinated individuals report a complication associated with
vaccination using replication competent strains of VV
(Fenner et al., 1988). Amongst the most serious complica-
tions is post-vaccination encephalitis, which is most common
in vaccinated infants (approximately 1 in 20,000 children
immunized with VV under the age of 1 year are diagnosed
with encephalitis). This complication has a 30–50% case0042-6822/$ - see front matter D 2005 Published by Elsevier Inc.
doi:10.1016/j.virol.2005.01.006
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vaccinia Ig.
The WR strain is a mouse-adapted, virulent strain of VV.
Intra-cerebral infection of susceptible mice with as little as
102 pfu of VV-WR is lethal. Intra-nasal infection of C57BL/
6 mice with this virus leads to replication in the nasal
mucosa and spread to the brain (Brandt and Jacobs, 2001).
Since in the intra-nasal model virus spreads from the
periphery to the brain, this model may be an appropriate
predictor of neurological complications associated with
vaccination. In fact, there appears to be a correlation
between neurovirulence of a strain of VV in the mouse
model and reactogenicity in humans (Fenner et al., 1988).
With the goal of defining the mechanisms by which
poxviruses evade host defenses we have been studying the
VV E3L gene. The E3L gene, which codes for two
C-terminal co-linear proteins, p20 and p25, is required for
interferon-resistance of VV (Jacobs and Langland, 1996),05) 263–270
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gene expression (Smith et al., 2001; Xiang et al., 2002). The
carboxy-terminal domain of E3L encodes a conserved motif
that functions to bind double-stranded RNA (dsRNA). This
dsRNA-binding domain has been studied in detail and is
required for inhibition of the cellular dsRNA-dependent
antiviral enzymes, PKR and 2V5V oligo-adenylate synthetase
(Chang and Jacobs, 1993; Rivas et al., 1998; Watson et al.,
1991). The importance of the amino terminus of E3L until
recently has been elusive. It is not required for IFN
resistance or host range of VV in cells in culture (Shors et
al., 1997); however, we have recently identified the amino
terminus as critical for pathogenesis in a mouse model
(Brandt and Jacobs, 2001).
The N-terminal domain of E3L shows sequence sim-
ilarity with a group of Z-DNA-binding proteins, ADAR-1
and Dlm (Kim et al., 2003). In fact, the N-terminus of E3L
can bind Z-DNA (Kim et al., 2004), and the related domains
from ADAR-1 and Dlm can partially complement deletion
of the N-terminal domain of E3L (Kim et al., 2003). Among
virus containing mutations in the N-terminal domain of E3L
or of an ADAR-1/E3L chimera, pathogenesis correlated
with affinity for Z-DNA (Kim et al., 2003).
VV (strain WR) expressing an amino terminal deletion
of 83 amino acids of E3L (VV-E3LD83N) is attenuated in
a mouse model by at least 1000-fold compared to wild-
type VV when administered via the intra-nasal route
(Brandt and Jacobs, 2001). These results led us to
investigate the specific role that the amino terminus may
be playing during a virus infection in mice. In this
manuscript we demonstrate that recombinant viruses
containing N-terminal deletions in E3L replicate effi-
ciently in the nasal mucosa but fail to spread from the
nasal cavity to the lungs or the brain. These virus
recombinants exhibit decreased virulence even when
injected directly into the brain, likely due to poor
replication in neuronal tissue. Intra-nasal infection or
infection by scarification with one of these replication
competent VV recombinants fully protected against
challenge with wild-type VV.Fig. 1. Dose–response mortality curves for intra-nasal infections with virus
recombinants containing N-terminal deletions of the E3L gene. Groups of at
least six C57BL/6 mice were infected intra-nasally with increasing doses of
the indicated viruses as described (see Materials and methods). Animals
were monitored for 2 weeks for morbidity, weight loss, and mortality (%
survival is shown).Results
Vaccinia viruses containing amino terminal deletions of the
E3L gene are attenuated in a mouse model
The N-terminus of the E3L gene is required for
pathogenicity in C57BL/6 or Balb/c mice (Brandt and
Jacobs, 2001; and data not shown). Intra-nasal infection
with as little as 104 pfu of wild-type VV killed 50% of
infected mice. In contrast, mice infected with VVE3LD83N
showed no mortality up to a dose of 106 pfu. The intra-nasal
LD50 for VVE3LD83N calculated from three independent
experiments was 2  107 pfu; greater than 1000 times
higher than wild-type VV (1  104 pfu).In order to determine whether the entire N-terminal
domain is required for pathogenesis we tested viruses
containing nested deletions in the N-terminus of E3L for
virulence by intra-nasal infection in the mouse model.
E3LD37N synthesizes only the smaller of the two proteins
encoded by E3L, p20. E3LD54N is missing approximately
half of the conserved N-terminal Z-DNA-binding domain,
while E3LD83N is missing the entire N-terminal Z-DNA-
binding domain (Kim et al., 2003). VVE3LD37N had an
LD50 of approximately 5  105 pfu after intra-nasal
infection (Fig. 1, open triangles), nearly 50-fold higher than
wild-type VV (Fig. 1, open squares). These results
demonstrate that expression of the full-length E3L encoded
protein (p25) is necessary to confer full pathogenesis to VV
in the mouse model. VVE3LD54N was completely apatho-
genic after intra-nasal infection with doses as high as 107
pfu (Fig. 1, open circles, and data not shown). The greater
reduction in pathogenicity of VVE3LD54N relative to
VVE3LD83N is likely due to instability of E3LD54N
protein (data not shown). Because of the instability of
E3LD54N protein this virus was not further characterized.
Amino terminal mutations decrease neuroinvasiveness of
vaccinia virus
The WR strain of VV used in these studies is neurotropic
and neurovirulent (Williamson et al., 1990). After intra-
nasal infection of C57BL/6 mice with the WR strain of VV,
the virus replicates to high titer in the nose, and then spreads
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titers (Brandt and Jacobs, 2001). Prior to euthanasia,
animals displayed neurological symptoms, including trem-
ors, seizures, and hyperactivity followed by lethargy. In
order to determine at which stage of the disease process
N-terminal deletion mutants are attenuated, animals were
infected intra-nasally with 105 pfu of either wild-type VVor
VVE3LD83N. Tissue was isolated from infected animals at
2, 4, and 6 days post-infection and assayed for the amount
of virus present. Fig. 2A shows results for wild-type VV.
Virus in the nasal cavity was detectable at 2 days post-
infection and peaked at 4 days post-infection with a titer
greater than 108 pfu/gm tissue. Virus spread to the lungs and
brain by 4 days post-infection. Results for VVE3LD83N are
shown in Fig. 2B. Virus was also detected in the nasal
cavities of animals infected with VVE3LD83N by 2 days
post-infection. Levels of VVE3LD83N increased through 6
days post-infection to a maximal titer indistinguishable fromFig. 2. Dissemination of virus after intra-nasal inoculation. Groups of 4- to
6-week-old C57BL/6 mice (mixed sex) were infected intra-nasally with 105
pfu of wild-type VV (panel A) or VVE3LD83N (panel B). At 2, 4, and 6
days post-infection animals were sacrificed in triplicate and nasal
turbinates, lung and brain tissue were harvested and titrated on RK-13
cell monolayer (see Materials and methods), as previously described
(Brandt and Jacobs, 2001). Data shown are representative of two
independent experiments.the peak titer in the nasal cavities of animals infected with
wild-type VV. Despite robust replication in nasal mucosa,
VVE3LD83N was not detected in the lungs or brain of
infected animals. Similar results were obtained for
VVE3LD54N and for sub-lethal doses of VVE3LD37N
(data not shown).
Amino terminal mutations decrease neurovirulence of
vaccinia virus
Since VV recombinants containing N-terminal deletions
in the E3L gene did not disseminate from the nose to the
brain as in a wild-type infection, it was important to assess
neurovirulence directly. Mice were infected intra-cranially
with increasing doses of wild-type VV, VVE3LD37N, or
VVE3LD83N and monitored for mortality. The results
revealed the same order of neurovirulence for these viruses
as after intra-nasal infection (wtVV N VVE3LD37N N
VVE3LD83N) (Fig. 3A). The LD50 for VVE3LD83N after
intra-cranial inoculation was approximately 1000-fold
higher than the LD50 for wild-type VV (1  105 pfu vs.
1  102 pfu, respectively). These results indicated that the
full-length N-terminus is required not only for spread from
the nasal cavity, but for pathogenesis after direct inoculation
in the brain as well.
In order to determine if the decrease in neurovirulence
was due to an inability of virus to replicate in neuronal tissue,
mice were inoculated intra-cranially with approximately 1 
106 pfu of wild-type VV or VVE3LD83N. Brains were
harvested 3 days post-infection and assayed for infectious
virus on RK13 cell monolayers (Fig. 3B). Wild-type VV
achieved titers greater than 109 pfu/gm of tissue, whereas
VVE3LD83N appeared not to replicate well in the brain,
yielding titers of less than 105 pfu/gm of tissue (Fig. 3B).
We have also monitored virus replication and spread with
strains of VV expressing lacZ from an intergenic locus.
Similar to virus not expressing a transgene, VVE3LD83N-
lacZ is 1000-fold less pathogenic than wtVV–lacZ (data not
shown). For wtVV–lacZ, virus spread from the site of
infection in the left hemisphere, with intense h-gal staining
throughout the choroid plexus of the lateral ventricles of the
brain (Fig. 4A). On the other hand, there was very little h-
gal staining in brains of animals infected with
VVE3LD83N-lacZ, and the staining was limited to the site
of infection (Fig. 4B). Taken together, these results indicate
that this mutant is defective in neurovirulence, likely due to
its inability to replicate to high titers in tissue of neuronal
origin, possibly in addition to a defect in spread from the
nasal mucosa.
The amino terminus of VV E3L is not required to elicit a
protective immune response
One of the primary complications to use of VV as a
vaccine is encephalitis (Fenner et al., 1988). The phenotype
of VVE3LD83N, replication to high titers in nasal mucosa
Fig. 4. Intra-cranial infection of mice: h-galactosidase staining of infected
cells. Four-week-old C57BL/6 mice were infected with 104 pfu of either
wtVV–lacZ (panel A), or VVE3LD83N-lacZ (panel B) in the left
hemisphere of the brain. At 6 days post-infection, brains were fixed by
perfusion as described in Materials and methods, removed from the skull,
cut into 2 mm blocks, and stained for h-galactosidase activity, using X-gal.
The view shown is an anterior view of a coronal section.
Fig. 3. Intra-cranial infection of mice: dose–response and viral replication.
Panel A: Groups of at least six anesthetized 4- to 6-week-old C57BL/6 mice
(mixed sex) were inoculated intra-cranially in the left hemisphere with 10 Al
of virus containing the indicated dose of virus. Animals were monitored
daily for weight loss and mortality. Panel A shows mortality curves for
intra-cranially infected mice. Panel B: To assay for virus replication in brain
tissue, mice were inoculated intra-cranially with 10 Al of virus containing
106 pfu. Mice were sacrificed in duplicate 5 days post-infection and brain
homoginates were assayed for infectious virus on RK-13 cell monolayers,
as described (Brandt and Jacobs, 2001).
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even when injected directly into the brain, suggested that
this virus might have characteristics of an improved vaccine
strain. In order to determine whether intra-nasal infections
with this virus could induce a protective immune response,
4-week-old mice were first infected intra-nasally with 10–
104 pfu of VVE3LD83N. Immunized animals were chal-
lenged intra-nasally 30 days later with 2  107 pfu of wild-
type VV (WR strain). Morbidity was assayed by monitoringloss of weight (Fig. 5). Mock-immunized, mock-challenged
animals gained weight during the course of the challenge,
while mock-immunized animals challenged with wild-type
VV lost 20% of their initial body weight over the 10-day
course of the challenge. Immunization with VVE3LD83N
protected against loss of weight caused by infection with
wild-type VV, in a dose-dependent manner. Immunization
with 10 pfu gave partial protection from weight loss, while
full protection was afforded by immunization with 100–
10,000 pfu of this virus (weight gain similar to mock
challenged control). Thus, VVE3LD83N protected mice
from challenge with wild-type VV at immunization doses
that were at least three logs lower than its LD50.
Vaccination against smallpox in humans is usually
performed by scarification. To determine if VVE3LD83N
could protect when administered by scarification, animals
were vaccinated with 106 pfu of either wtVV or
VVE3LD83N by scarification on the tail. With either virus
all vaccinated animals developed pocks, and there was no
significant difference in size or intensity of inflammation
between pocks induced by wtVV and VVE3LD83N.
Animals were challenged intra-nasally 3 months later with
106 pfu of wtVV (WR strain). Mock-vaccinated animals lost
20% of their body weight during the first 8 days of the
challenge (Fig. 6, open boxes). Animals vaccinated by
scarification with either wtVV (Fig. 6, open triangles) or
Fig. 5. Intra-nasal vaccination of mice against wild-type vaccinia virus infection (WR strain) using VVE3LD83N. Groups of five anesthetized C57BL/6 mice
were vaccinated intra-nasally with 10, 100, 1000, or 10,000 pfu of VVE3LD83N or buffer (mock vaccination). Mice were challenged intra-nasally with 2  107
pfu of wild-type VV, or mock challenged 30 days following initial infection. Data show mean change in body weight after challenge.
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protected from challenge with wtVV.
The WR strain of VV used in these experiments is a
neurovirulent, mouse adapted strain. To determine if an
N-terminal mutation in E3L would affect pathogenicity and
efficacy of a human vaccine strain we performed similar
experiments with the Copenhagen strain of VV and
Copenhagen-VVE3LD83N. WT-Copenhagen-VV was not
pathogenic when administered intra-cranially into immune
competent mice (data not shown) but was pathogenic when
administered intra-cranially in SCID mice (Fig. 7, open
diamonds). One of five mice infected intra-cranially withFig. 6. Scarification vaccination of mice against wild-type vaccinia virus
infection (WR strain) using VVE3LD83N. Groups of five anesthetized
BALB/c mice were vaccinated by scarification with 106 pfu of wtVV,
VVE3LD83N. Five anaesthetized mice were mock vaccinated with buffer
(1 mM Tris pH 8.8). Mice were challenged intra-nasally with 106 pfu of
wild-type VV, or mock challenged 90 days following initial infection. Data
show mean change in body weight after challenge.105 pfu of wt-Copenhagen-VV died on day 4, and the
remaining mice lost weight throughout the course of the
experiment (25% weight loss by day 15). Mice infected with
the same dose of Copenhagen-VVE3LD83N (Fig. 7, open
triangles) lost a small amount of weight on day 2 but fully
recovered and gained weight in a manner indistinguishable
from historic controls (data not shown). Thus, deletion of
the N-terminus of E3L further attenuated the already
attenuated Copenhagen vaccine strain. Mice vaccinated
with Copenhagen-VVE3LD83N by scarification were fully
protected from challenge with wt-WR-VV (Fig. 8).Discussion
In this manuscript we demonstrate that while the
N-terminal domain of the E3L gene product is not necessary
for efficient replication in the nasal mucosa, it is necessaryFig. 7. Pathogenicity of Copenhagen strain vaccinia viruses in SCID mice.
Groups of three female SCID mice were infected intra-cranially with 105
pfu of either wt-Copenhagen-VV (VC2, open diamonds) or Copenhagen-
VVE3LD83N (open triangles). Animals were monitored for weight loss and
mortality for 3 weeks. Crosses indicate dead animals (day 4) or animals that
were euthanized due to severe weight loss (day 20).
Fig. 8. Scarification vaccination of mice against wild-type vaccinia virus
infection (WR strain) using Copenhagen-VVE3LD83N. Groups of five
anesthetized BALB/c mice were vaccinated by scarification with 106 pfu of
wt-Copenhagen-VV (VC2, open triangles) or Copenhagen-VVE3LD83N
(del83N, open circles). Five anaesthetized mice were mock vaccinated with
buffer (Mock/Challenge, open squares). Mice were challenged intra-nasally
with 106 pfu of wild-type VV, or mock challenged (Mock, open diamonds)
30 days following initial infection. Data show mean change in body weight
after challenge.
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for efficient replication in the brain. Recombinant virus
containing an E3L gene deleted of the N-terminal domain
is fully replication competent in most cells in culture
(Shors et al., 1997). The virus also replicated to wild-type
levels in nasal tissues but failed to spread from the nasal
cavity either to the lungs or the brain. Despite replicating
in the nasal mucosa, intra-cranial injection into the brain
showed that this virus replicated poorly, if at all, in
neuronal tissue. Thus this virus demonstrates a tissue
specific host-range phenotype.
While the N-terminus of E3L is not necessary for
replication in cells in culture, several biochemical character-
istics have been mapped to this domain. The E3L gene
products are found both in the nucleus and cytoplasm of
infected cells (Yuwen et al., 1993). We have shown that the
N-terminus is required for nuclear localization of the E3L
gene products: E3LD83N is excluded from the nucleus of
infected cells (Chang et al., 1995). The role of nuclear
localization in pathogenesis in mice is at present unclear.
The N-terminus of E3L has homology to the Z-DNA-
binding domain (Za) of the RNA-editing enzyme, ADAR-1
(Kim et al., 2003). The E3L gene products bind to Z-DNA,
although with lower affinity than ADAR-1 (Kahmann et al.,
2004). We have recently shown that the ADAR-1 Za
domain can complement the N-terminus of E3L for neuro-
virulence, and that neurovirulence correlates with binding to
Z-DNA among mutants of E3L and an ADAR-1 Za/E3LdsRNA-binding domain chimera (Kim et al., 2003). While
the ADAR-1 Za can complement loss of the N-terminus of
E3L for intra-cranial infection (neurovirulence), the ADAR-
1 Za complements poorly on intra-nasal infection (Mur-
alinath, Hauns and Jacobs, unpublished observations),
suggesting that the N-terminus has two separable functions
for spread from the nasal cavity and neurovirulence.
The E3L gene products can inhibit activity of ADAR-1
and the N-terminus of E3L has been implicated in this
inhibition of enzyme activity (Liu et al., 2001). Since
ADAR-1 is highly expressed in brain (Paul and Bass, 1998),
it is possible that the failure to inhibit ADAR-1 in the brain
may be responsible for the decrease in neurovirulence of
viruses containing N-terminal mutations in E3L.
The E3L gene products are potent inhibitors of the anti-
viral enzymes PKR and OAS (Jacobs and Langland, 1996),
and the N-terminal domain is necessary for inhibition of
these enzymes at very late times post-infection in cells in
culture (Langland and Jacobs, 2004). While failure to inhibit
PKR and OAS at very late times post-infection does not lead
to any phenotypic difference in cells in culture, it is possible
that it is responsible for some of the phenotypes seen in
infected animals. Consistent with this, VVE3LD83N led to
high levels of eIF2a phosphorylation (eIF2a is the main
substrate for active PKR in infected cells) in the nose, but not
the brain of infected animals (Langland and Jacobs, 2004).
Vaccinia virus is the vaccine for protection against
smallpox and is being developed as a vector for immuniza-
tion against heterologous pathogens and cancer. The current
vaccine strains for protection against smallpox cause a
relatively high rate of complications, including encephalitis
in young children (Fenner et al., 1988). Development of a
safer vaccine that can protect against smallpox is a high
priority. Since VVE3LD83N replicated to wild-type titers at
the site of infection, but failed to spread, and was reduced
over 1000-fold in terms of neurovirulence, we investigated
its ability to immunize against challenge with pathogenic
wild-type VV. Immunization of 4-week-old mice intra-
nasally with 100–10,000 pfu of VVE3LD83N fully pro-
tected against challenge 4 weeks later with a large dose of
wild-type VV. Thus a protective dose is from 3 to 5 logs
lower than a pathogenic dose with this virus. Vaccination
with this virus by scarification also protected against an
intra-nasal challenge with wtVV. These results demonstrate
that this replication competent, attenuated mutant of VV can
indeed induce a protective immune response in mice. It is
likely that any vaccine based on a similar mutation in the
E3L gene would cause fewer complications in humans than
a wild-type VV-based vaccine. In fact, Copenhagen-
VVE3LD83N is attenuated compared to the parental
vaccine strain but still induces a protective immune response
in vaccinated mice.
Vaccinia viruses containing attenuating mutations in
other non-essential genes have been studied as potential
vaccines (Buller et al., 1985; Lee et al., 1992; Legrand et al.,
2004; Verardi et al., 2001). Mutation of the TK gene of VV
T. Brandt et al. / Virology 333 (2005) 263–270 269decreases neurovirulence to approximately the same level as
the E3LD83N mutation, while having no effect on
replication in cells in culture (Buller et al., 1985; Lee et
al., 1992). Mutation of serpin genes or the IFNg receptor
homologue also attenuates, without affecting immunoge-
nicity developed toward a heterologous antigen (Legrand et
al., 2004; Verardi et al., 2001). However, it is not possible to
compare the level of attenuation of these viruses relative to
VVE3LD83N. Protection against challenge with a patho-
genic poxvirus has not been reported for these other
attenuated strains of VV.Materials and methods
Virus construction
Viruses were constructed by targeted in vivo recombi-
nation (IVR) of WRDE3L with pMPDE3L plasmid encod-
ing the respective mutant E3L gene (D37N, D54N, or
D83N) cloned between homologous recombination flanking
arms as previously described (Brandt and Jacobs, 2001;
Kibler et al., 1997). Wild-type E3L reconstruction revertants
were then made by recombination of the wild-type E3L
gene into mutant viral constructs. Insertion of the Escher-
ichia coli lacZ gene into the intergenic region between E2L
and E3L will be described elsewhere.
Cell culture
RK13 cells were cultured in MEM (Gibco, BRL)
containing 5% FBS, 50 Ag/ml gentamycin, and 0.1 mM
non-essential amino acid solution (MEM5%) (Gibco, BRL).
Cells were incubated at 37 8C with 5% CO2. BHK-21 cells
were cultured in MEM (Gibco, BRL) containing 10% FBS
and 50 Ag/ml gentamycin (MEM10%) and incubated at 37
8C with 5% CO2. HeLa S3 cells were cultured in DMEM
(Gibco, BRL) with 5% FBS (DMEM5%) and incubated at
37 8C with 5% CO2.
In vivo infections
C57BL/6 and BALB/c breeders were obtained from
Charles River, and colonies were maintained pathogen-free
by the Animal Resource Center at Arizona State University.
SCID mice (CB17) were obtained directly from Charles
River. Four- to five-week-old mice were randomized such
that each cage contained at least 6 mice with approximately
equal average body weight and equal numbers of each sex.
A separate cage was used for each experimental condition
(dose of each virus). An anesthetic cocktail was prepared
containing 7.5 mg/ml xylazine (Phoenix Pharmaceuticals,
St. Joseph, Missouri), 2.5 mg/ml acepromazine maleate, and
37.5 mg/ml ketamine (Fort Dodge Laboratories, Fort
Dodge, Iowa). Approximately 1 Al of cocktail was injected
per gram of mouse weight via the intra-muscular route.Following anesthesia, virus was administered intra-nasally
(using pipetman with a gel loading tip) in doses containing
103–108 pfu VV in 5 Al 1mM Tris, pH 8.8. Mice were
observed daily for body weight loss and morbidity (Reed
and Muench, 1938).
Intra-cranial inoculations were performed following
anesthesia as above. Ten microliters of virus containing
various titers of virus in 1 mM Tris pH 8.8 was injected
intra-cranially using a 26-gauge hypodermic needle and 1 cc
syringe (B–D). Weight loss was determined by weighing
individual mice every day or on alternate days post-
infection. The percent weight gain or loss over time was
determined simply by averaging the weights per cage at
each time point divided by the initial average weight.
For infection by scarification, fur was removed from the
skin at the base of the tail of BALB/c mice using Nair hair
remover and 15 scratches were made horizontally across the
tail using a 26-gauge needle. Ten microliters of virus in
1 mM Tris, pH 8.8, was pipetted onto the abraded skin and
rubbed in with the side of the pipette tip.
Tissue distribution
C57BL/6 mice between 4 and 5 weeks old were
randomized so that each cage contained equivalent number
of males and females. The mice were anesthetized and
infected intra-nasally or intra-cranially, as described above.
Three mice inoculated with each virus recombinant and
three uninfected controls were sacrificed on days 2, 4, and 6
post-infection and the brain, lungs, and nasal turbinates
were harvested and frozen in liquid nitrogen. Each tissue
was homogenized (nasal turbinates required additional
grinding with sand) on ice and made into 10% tissue
suspensions using MEM containing 5% FBS and 100 Ag/ml
of gentamycin. Tissue suspensions underwent three rounds
of freezing (80 8C) and thawing (37 8C) and cell debris
was removed by centrifugation (4 8C). Virus titers were
determined for tissue samples by titration using RK-13 cell
monolayers.
For the histochemical identification of VV replication in
brains, 4- to 5-week-old C57bl/6 (Charles Rivers Labo-
ratory) were anesthetized prior to intra-cranial injection of
104 pfu of wtWR-lacZ or WR-E3LD83N-lacZ (lacZ inserted
into the intergenic region between E3L and E3L; construc-
tion of these viruses will be described elsewhere) into the
left hemisphere. Brains were removed 4 days post-infection
after cardiac perfusion with 4% paraformaldehyde in PBS
(pH 7.4). The tissues were saturated with 30% sucrose,
sliced using a 2-mm tissue block, and stained with X-gal
solution as previously described (Bloom and Jarman, 1998).Acknowledgments
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